{
    "clinical_study": {
        "@rank": "132911", 
        "arm_group": [
            {
                "arm_group_label": "Infusion of autologous mononuclear bone marrow cells", 
                "arm_group_type": "Experimental", 
                "description": "Infusion of autologous mononuclear bone marrow cells more conventional medical treatment"
            }, 
            {
                "arm_group_label": "Placebo infusion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo infusion more conventional medical treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical trial phase III, double-blind, randomized, controlled with placebo. There is\n      sufficient preliminary evidence to consider intracoronary injection of bone marrow\n      progenitor cells as a viable, safe and beneficial treatment in patients with dilated\n      cardiomyopathy, although the biological mechanism of action of bone marrow cells in the\n      myocardium is not known. In this project we propose to investigate comparatively and from a\n      biological and clinical point of view the applicability of regenerative therapy with\n      autologous bone marrow cells in patients with dilated cardiomyopathy."
        }, 
        "brief_title": "Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells os Bone Marrow on Functional Recovery in Patients With Dilated Cardiomyopathy and Heart Failure.", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Dilated Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Dilated", 
                "Heart Failure", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study population correspond to male and female patients with idiopathic dilated\n      cardiomyopathy.\n\n      51 patients diagnosed with this disease are included. After inclusion, will proceed to the\n      random allocation to study group or control group in a 2:1 ratio, 34 patients in the\n      treatment group and 17 in the control group.\n\n      The total duration is expected to be 36 months: The inclusion period is 24 months and each\n      patient will be followed for 12 months. Upon completion thereof, the patients will be\n      followed in routine clinical practice.\n\n      This is a double blind study, in which all patients were will perform the bone marrow\n      harvesting.\n\n      All patients will receive the best medical treatment individualized (ACEIs or Angiotensin II\n      receptor blocker, beta-blockers, diuretics and eplerenone) for at least 6 months prior to\n      their participation in the clinical trial, so that the situation is stable and\n      pharmacological basal condition is the same for everyone.\n\n      The bone marrow cells of patients assigned to placebo group will be cryopreserved, and once\n      the trial is completed, the blind will be opened and all the patients who had been\n      randomized to the control group, may be processed by the route of compassionate use with\n      their own mononuclear bone marrow cells previously frozen.\n\n      Randomization of patients, will be centralized by the sponsor or contract research\n      organization designated for such purpose. In both treatment groups will be stratified by a\n      condition (age> or \u2264 45 years). The final probability of treatment assignment will be\n      conditioned by the number of patients included in each group (2:1) and the number of\n      patients who meet the inclusion each condition.\n\n      The main objective is to assess comparative the efficacy of intracoronary injection of bone\n      marrow stem cells autologous to improve ventricular function in patients with idiopathic\n      dilated cardiomyopathy who receive conventional medical treatment, compared with a control\n      group who receive a infusion of placebo and conventional medical treatment. The improvement\n      in ventricular function assessed by changes in angiographically determined ejection\n      fraction.\n\n      Secondary objectives of the study are:\n\n      - To analyze the predictors of good clinical response, functional and biological treatment\n      with adult stem cells autologous mononuclear bone marrow not expanded in terms of functional\n      recovery.\n\n      The following parameters were evaluated: Functional class (NYHA), natriuretic peptide B,\n      stress test (exercise time) and echocardiographic parameters of ventricular function.\n\n      - To determine, in the light of the obtained results, the application protocol suitable cell\n      therapy for the treatment of dilated cardiomyopathy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients of both sexes and ages between 18 and 70 years.\n\n          2. Patients diagnosed with dilated cardiomyopathy established by echocardiography with\n             symptoms and / or signs of heart failure of idiopathic etiology.\n\n          3. Minimum evolution since diagnosis 6 months\n\n          4. Absence of coronary lesions tested with multislice CT and / or hemodynamic study\n\n          5. Patients with stable medical therapy for at least 6 months prior to enrollment\n             (either individually adjusted according to B-type natriuretic peptide  and functional\n             status).\n\n          6. Ejection fraction of the left ventricle <40% or ejection fraction of the left\n             ventricle 40% -50% if left ventricular tele-diastolic volume> 110 ml/m2.\n\n          7. Presence of sinus rhythm.\n\n          8. Patients give their informed consent for participation in the clinical trial consent.\n\n          9. Normal laboratory parameters, defined by:\n\n               -  Leukocytes \u2265 3000\n\n               -  Neutrophils \u2265 1500\n\n               -  Platelets \u2265 100,000\n\n               -  Aspartate aminotransferase / Alanine aminotransferase \u2264 2.5 standard range\n                  institution\n\n               -  Creatinine \u2264 2.5 mg / dl\n\n         10. Women of childbearing potential must have negative results on a pregnancy test at the\n             time of inclusion in the study and agree to use a medically approved method of\n             contraception while on study.\n\n        Exclusion Criteria:\n\n          1. Dilated cardiomyopathy of toxic origin, or ischemic storage diseases.\n\n          2. Recent history of myocarditis.\n\n          3. Patients amenable to treatment with resynchronization\n\n          4. Patients in active waiting list for heart transplantation.\n\n          5. Coexistence of other serious systemic diseases.\n\n          6. Coexistence of any type of blood disease\n\n          7. Pregnant women, lactating, or of childbearing age not using effective contraception.\n\n          8. Patients who are currently participating or have completed their participation in a\n             clinical trial at a period less than 3 months.\n\n          9. Patients with malignant or pre-malignant tumors\n\n         10. Positive serology for hepatitis B virus, hepatitis C virus or human immunodeficiency\n             virus.\n\n         11. Patients at the time of study entry are taking any medications prohibited by the\n             protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033278", 
            "org_study_id": "CMMo/MD/2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Infusion of autologous mononuclear bone marrow cells", 
                "description": "Infusion of autologous mononuclear bone marrow cells more conventional medical treatment", 
                "intervention_name": "Infusion of autologous mononuclear bone marrow cells", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo infusion", 
                "description": "Placebo infusion more conventional medical treatment", 
                "intervention_name": "Placebo infusion", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 9, 2014", 
        "link": {
            "url": "http://www.juntadeandalucia.es/terapiasavanzadas/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Manuel Sancho Jald\u00f3n, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "C\u00e1diz", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Puerta del Mar"
                }, 
                "investigator": {
                    "last_name": "Manuel Sancho Jald\u00f3n, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain"
                    }, 
                    "name": "Hopistal Universitario Reina Sof\u00eda"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eduardo de Teresa Galv\u00e1n, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain"
                    }, 
                    "name": "Hopistal Universitario Virgen de la Victoria"
                }, 
                "investigator": {
                    "last_name": "Eduardo de Teresa Galv\u00e1n, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Luis Pastor Torre, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41014"
                    }, 
                    "name": "Hospital Universitario de Valme"
                }, 
                "investigator": {
                    "last_name": "Luis Pastor Torre, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Phase III Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Dilated Cardiomyopathy and Heart Failure.", 
        "overall_contact": {
            "email": "ana.cardesa@juntadeanlacia.es", 
            "last_name": "Ana Cardesa", 
            "phone": "0034 955014090"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Universitario Reina Sof\u00eda", 
                "last_name": "Jos\u00e9 Su\u00e1rez de Lezo Cruz Conde, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario Virgen de la Victoria", 
                "last_name": "Eduardo de Teresa Galv\u00e1n, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario de Valme", 
                "last_name": "Luis Pastor Torre, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario Puerta del Mar", 
                "last_name": "Manuel Sancho Jald\u00f3n, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in ventricular function determined angiographically", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033278"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Degree of clinical improvement based on the absence of major cardiac events (MACE) during follow-up", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Presence or absence of symptoms or arrhythmias", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Evolution time since diagnosis of idiopathic dilated cardiomyopathy to the inclusion of the patient.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud", 
        "sponsors": {
            "collaborator": {
                "agency": "Iniciativa Andaluza en Terapias Avanzadas", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}